This site is intended only for healthcare professionals resident in the United Kingdom

Information relating to specific disease areas aligned to Pfizer’s portfolio and other resources designed for Pfizer medicines.

See all Therapy areas

Information on how to access Genotropin® (somatropin, rbe) prescribing information and adverse event reporting can be found at the bottom of the page.

Efficacy of Genotropin in the treatment of growth disturbance associated with Turner Syndrome

Genotropin is indicated for the treatment of growth disturbance in children associated with Turner Syndrome.

Turner syndrome is a chromosomal disorder characterised by the complete or partial lack of one X chromosome in girls. The two most common clinical features are short stature and ovarian failure.4

Not all girls with Turner syndrome will need treatment with Genotropin, but if the condition is untreated when indicated, girls with Turner syndrome will have a final adult height of 136–147 cm which on average is 20 cm shorter than other adult women.4

Turner syndrome occurs in between 1 in 1500 and 1 in 2500 live female births.​​​​​​​4

Efficacy of Genotropin in the treatment of Turner Syndrome

Normalisation of height with induction of puberty at an appropriate time1,2

Significant improvement in height standard deviation score (SDS) relative to TS-specific height references (p < 0.05), in girls with TS treated to near adult height (NAH).

Normalisation of height with induction of puberty at an appropriate time1,2

Significant improvement in height standard deviation score (SDS) relative to TS-specific height references (p < 0.05), in girls with TS treated to near adult height (NAH).

Maximisation of height with the early introduction of growth hormone (GH) therapy allows for the timely induction of puberty with oestrogen in patients with TS 1,2

Adapted from Ranke et al, 20071.

Study methods

Height SDS data reported at GH start (mean age 9.7 years), 1st year and puberty from 1,146 TS girls from published data, treated to near final height (mean dose of 0.28 mg/kg body weight/week).​​​​​​​​​

Turner Syndrome

Watch Dr Helen Turner talk about the early diagnosis of Turner syndrome, the commonest chromosomal disorder in women 

Dosing3

Dosage recommendations in Turner Syndrome Patients

Indication

mg/kg body weight dose per day

mg/m2 body surface area dose per day

Turner Syndrome

0.045-0.050

1.4

Please refer to the Summary of Product Characteristics for full information before prescribing Genotropin

Safety​​​​​​​3

Adverse events in the long-term treatment of Children with Growth Disturbance due to Turner syndrome

Long-term Treatment of Children with Growth Disturbance due to Turner syndrome

System Organ Class

Very Common ≥ 1/10

Common ≥ 1/100 to <1/10

Uncommon ≥ 1/1,000 to <1/100

Rare ≥ 1/10,000 to <1/1,000

Very Rare <1/10,000

Not Known (cannot be estimated from available data)

Neoplasms Benign, Malignant and Unspecified (including cysts and polyps)

Leukaemia

Metabolism and Nutrition Disorders

Type 2 diabetes mellitus

Nervous System Disorders

Paraesthesia*

Benign intracranial hypertension

Skin and Subcutaneous Tissue Disorders

Rash**

Pruritus**

Urticaria**

Musculoskeletal, Connective Tissue and Bone Disorders

Arthralgia*

Myalgia*

Musculoskeletal stiffness*

General Disorders and Administration Site Conditions

Oedema peripheral*

Face oedema*

Injection site reaction$

Investigations

Blood cortisol decreased

*In general, these adverse effects are mild to moderate, arise within the first months of treatment, and subside spontaneously or with dose-reduction. The incidence of these adverse effects is related to the administered dose, the age of the patients, and possibly inversely related to the age of the patients at the onset of growth hormone deficiency.
** Adverse Drug Reactions (ADR) identified post-marketing
$ Transient injection site reactions in children have been reported.
Clinical significance is unknown
Reported in growth hormone deficient children treated with somatropin, but the incidence appears to be similar to that in children without growth hormone deficiency.
Abbreviations: TS, turner syndrome; SDS, standard deviation score; NAH, near adult height; GH, growth hormone.

Explore more

NICE technology appraisal guidance

Find out more about NICE’s technology appraisals on the use of Genotropin for Adult Growth Hormone Deficiency

Find out more

Endocrine helpline 

Our dedicated nurse team are on hand to support patients being treated with Genotropin and healthcare professionals who have Genotropin patients

Contact the team


References:
  1. Ranke MB, Price DA, Reiter EO, 2007. Basel, Karger, pp 332–339.
  2. Ranke MB, Price DA, Reiter EO, 2007. Basel, Karger, pp 326–331.
  3. Genotropin Summary of Product Characteristics. Accessed here.
  4. NICE Guidance [TA188]. Human growth hormone (somatropin) for the treatment of growth failure in children. Accessed here
PP-GEN-GBR-1072. April 2021

Starter kits

A choice of personalised starter kits is available to child and adult Genotropin patients to make sure they get off to a good start with their treatment

Learn more

The Genotropin Delivery portfolio

Learn more about the 3 devices available for Genotropin patients

Learn more

For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-PFE-GBR-2688. December 2020

Yes

No